{"filing":{"accession_number":"0001628280-26-047590","cik":"0001894562","ticker":"PRME","company_name":"Prime Medicine, Inc.","form":"8-K","filing_date":"2026-07-08","report_date":null,"primary_document":"prme-20260706.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1894562/000162828026047590/prme-20260706.htm"},"events":[{"id":16611,"run_id":14843,"accession_number":"0001628280-26-047590","anchor_item_number":"8.01","event_type":"material_litigation","event_domain":"legal","is_material":true,"confidence":0.92,"summary":"Prime Medicine disclosed a final arbitration award resolving a material dispute with Beam Therapeutics over the 2019 Collaboration and License Agreement. The Tribunal ruled in Prime's favor, declaring PM647 falls within Prime's \"Field\" and denying Beam's claims for damages and injunctive relief. This favorable resolution of a material contractual dispute affecting the Company's development rights is a significant legal event that would affect a reasonable investor's assessment of Prime's ability to continue developing PM647 for AATD.","company_name":"Prime Medicine, Inc.","ticker":"PRME","filing_date":"2026-07-08","form":"8-K","submitted_at":null,"items":[{"id":14764,"accession_number":"0001628280-26-047590","item_number":"8.01","item_title":"Other Events","event_type":"material_litigation","event_domain":"legal","is_material":true,"confidence":0.92,"reasoning":"Prime Medicine disclosed a final arbitration award resolving a material dispute with Beam Therapeutics over the 2019 Collaboration and License Agreement. The Tribunal ruled in Prime's favor, declaring PM647 falls within Prime's \"Field\" and denying Beam's claims for damages and injunctive relief. This favorable resolution of a material contractual dispute affecting the Company's development rights is a significant legal event that would affect a reasonable investor's assessment of Prime's ability to continue developing PM647 for AATD.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-08T12:03:37.023202+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":14764,"accession_number":"0001628280-26-047590","item_number":"8.01","item_title":"Other Events","event_type":"material_litigation","event_domain":"legal","is_material":true,"confidence":0.92,"reasoning":"Prime Medicine disclosed a final arbitration award resolving a material dispute with Beam Therapeutics over the 2019 Collaboration and License Agreement. The Tribunal ruled in Prime's favor, declaring PM647 falls within Prime's \"Field\" and denying Beam's claims for damages and injunctive relief. This favorable resolution of a material contractual dispute affecting the Company's development rights is a significant legal event that would affect a reasonable investor's assessment of Prime's ability to continue developing PM647 for AATD.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-08T12:03:37.023202+00:00","company_name":"Prime Medicine, Inc.","ticker":"PRME","filing_date":"2026-07-08"}]}